PHVS - Pharvaris NV
IEX Last Trade
18.015
0.715 3.969%
Share volume: 453,119
Last Updated: Fri 30 Aug 2024 09:59:49 PM CEST
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
0.87%
PREVIOUS CLOSE
CHG
CHG%
$17.30
0.72
4.13%
Fundamental analysis
4%
Profitability
0%
Dept financing
0%
Liquidity
0%
Performance
10%
Performance
5 Days
0.84%
1 Month
5.39%
3 Months
-4.76%
6 Months
-25.65%
1 Year
-9.59%
2 Year
98.90%
Key data
Stock price
$18.02
DAY RANGE
N/A - N/A
52 WEEK RANGE
$15.00 - $33.00
52 WEEK CHANGE
-$0.16
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
Company detail
CEO:
Region: US
Website: pharvaris.com
Employees: 68
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: pharvaris.com
Employees: 68
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
pharvaris is a preclinical stage company focused on bringing an oral bradykinin b2 receptor antagonist to patients for use as an alternative to injected therapies for hereditary angioedema (hae) and other b2 receptor-mediated indications. the company reunites the core team responsible for the discovery and approval of the hae treatment icatibant. with novel small molecules, we have identified and are advancing potent, orally available compounds targeting this clinically proven therapeutic target.
Recent news